ClinicalTrials.gg
TerminatedNCT05036291Updated Apr 22, 2026

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

A Phase 1 interventional study of NB004 tablets in Advanced Solid Tumor, sponsored by Ningbo Newbay Technology Development Co., Ltd. Terminated at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Ningbo Newbay Technology Development Co., Ltd · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Development change

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered as Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors

Read the detailed description

This study is a Phase 1, open-label, multicenter study of NB004 administered orally in patients with histologically and/or cytologically confirmed diagnosis of advanced solid tumors that are metastatic for which all standard treatment options have been given and are ineffective, or is no longer eligible for additional standard treatment options.

The study is comprised of a dose escalation phase to determine the maximum tolerated dose and the RP2D and an expansion phase to further explore the safety and preliminary antitumor activity of NB004.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Ningbo Newbay Technology Development Co., Ltd is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. males or females of any race>(=)18 years age.
  2. and/or cytologically confirmed diagnosis of advanced solid tumors that are without standard treatment options (part 1).

    Pathologically confirmed locally advanced or solid tumors with KRAS G12C mutation as determined by a test that has been approved by FDA or local health authority (part 2\&3).

  3. (ECOG) performance status of 0 or 1.
  4. >(=)12 weeks.
  5. Adequate organ and marrow function.
  6. Measurable or evaluable disease.

Exclusion criteria

Exclusion Criteria:

  1. Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum of 3 weeks, before the first dose.
  2. Toxicities from previous anti-cancer therapy that have not recovered as required.
  3. Brain disease, spinal cord compression, or .
  4. Active infection including , , and (HIV):
  5. Female subjects who are pregnant, or breastfeeding, or planning to become pregnant while in this study or within 3 months after the last dose.
  6. Male subjects who plan to father a child while enrolled in the study or within 3 months after the last dose.
  7. Received prior treatment with a PIM kinase inhibitor.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    NB004

    Part1: Dose escalation phase of study drug NB004 monotherapy: Part 2: Dose Escalation Phase for the NB004 in combination with Sotorasib: Part 3: COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:

    Drug: NB004 tablets

Interventions

  • DrugNB004 tablets

    Part1: Dose escalation phase of study drug NB004 monotherapy: Drug: NB004 tablets NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met. Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib: Drug: NB004 tablets \& Sotorasib NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met. Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib: Drug: NB004 tablets \& Sotorasib NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met. Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA .

    Also known as: Sotorasib

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities----Part 1/2

    Dose-limiting toxicities will be reviewed as a subset of adverse events that occurs within the first 28 days of dosing and meet protocol-specified criteria.

    Time frame: When subject complete 1 cycle (28 days) treatment with safety and tolerability assessment by investigators.

  2. Incidence of adverse events----Part 1/2

    An adverse event is any untoward medical occurrence in a participant who received study drug without regard to causal relationship.

    Time frame: Approximately 24 months since the first subject enrolled

  3. Objective Response Rate (ORR) ----Part 3

    Objective Response Rate (ORR) is defined as the percentage of patients whose efficacy is confirmed as complete response (CR) or partial response (PR)

    Time frame: [Time Frame: Approximately 24 months since the first subject enrolled]

  4. Duration of Response (DOR) ----Part 3

    DOR is defined as the time from the date of first documented response until date of documented progression, for subjects who achieve CR or PR.

    Time frame: [Time Frame: Approximately 24 months since the first subject enrolled]

  5. Time to Response (TTR) ----Part 3

    TTR is defined as the time interval between the date of first administration and the date of the first recording of response. At the same time, the initial response time and the time to best response will be calculated.

    Time frame: [Time Frame: Approximately 24 months since the first subject enrolled]

  6. Progression-free Survival (PFS) ----Part 3

    PFS is defined as the time from the date of the first dose until the date of disease progression, as defined by RECIST v1.1, or death.

    Time frame: [Time Frame: Approximately 24 months since the first subject enrolled]

  7. Clinical Benefit Rate (CBR) ----Part 3

    CBR is defined as the number of subjects with CR or PR or with SD maintained ≥24 weeks (as assessed by the Investigator, using RECIST v1.1) divided by the number of subjects in the analysis. Subjects without a postbaseline tumor assessment will be considered as having no clinical benefit.

    Time frame: [Time Frame: Approximately 24 months since the first subject enrolled]

  8. Overall survival (OS) ----Part 3

    OS is defined as the time from treatment start with study drug until event of death due to any cause.

    Time frame: [Time Frame: Approximately 24 months since the first subject enrolled]

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax)----Part 1

    Maximum observed plasma concentration (Cmax)

    Time frame: Approximately 24 months since the first subject enrolled

  2. Time to Cmax (Tmax)----Part 1

    Time to Cmax (Tmax)

    Time frame: Approximately 24 months since the first subject enrolled

  3. Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t) ----Part 1

    AUC (0-t) = Area under the serum concentration versus time curve from time zero (pre-dose) to the time of the last

    Time frame: Approximately 24 months since the first subject enrolled

  4. Terminal elimination half life----Part 1

    Terminal elimination half life

    Time frame: Approximately 24 months since the first subject enrolled

  5. Objective Response Rate (ORR)----Part 2

    Objective Response Rate (ORR) is defined as the percentage of patients whose efficacy is confirmed as complete response(CR) or partial responses(PR)

    Time frame: Approximately 24 months since the first subject enrolled

  6. Duration of Response(DOR)----Part 2

    DOR is defined as the time from the date of first documented response until date of documented progression, for subjects who achieve CR or PR.

    Time frame: Approximately 24 months since the first subject enrolled

  7. Clinical Benefit Rate (CBR) ----Part 2

    CBR is defined as the number of subjects with CR or PR or with SD maintained ≥24 weeks (as assessed by the Investigator, using RECIST v1.1) divided by the number of subjects in the analysis. Subjects without a postbaseline tumor assessment will be considered as having no clinical benefit.

    Time frame: [Time Frame: Approximately 24 months since the first subject enrolled]

  8. Time to Response (TTR) ----Part 2

    TTR is defined as the time interval between the date of first administration and the date of the first recording of response. At the same time, the initial response time and the time to best response will be calculated.

    Time frame: [Time Frame: Approximately 24 months since the first subject enrolled]

  9. Progression-free Survival (PFS) ----Part 2

    PFS is defined as the time from the date of the first dose until the date of disease progression, as defined by RECIST

    Time frame: [Time Frame: Approximately 24 months since the first subject enrolled]

  10. Overall survival (OS) ----Part 2

    OS is defined as the time from treatment start with study drug until event of death due to any cause

    Time frame: [Time Frame: Approximately 24 months since the first subject enrolled]

07

Study locations

4 sites
  • LSU-LCMC Health Cancer Center
    New Orleans, Louisiana 70112, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • National Cheng Kung University Hospital(NCKUH)
    Tainan, Taiwan 008866, China
  • National Taiwan University Hospital Yunlin Branch
    Yunlin, Taiwan 886, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Sep 2025, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2021
First posted
Sep 5, 2021
StartActual
Oct 1, 2021
Primary completionActual
Sep 24, 2025
CompletionActual
Oct 10, 2025
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05036291
Lead sponsor
Ningbo Newbay Technology Development Co., Ltd
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Oct 1, 2021
Primary completion
Sep 24, 2025
Completion
Oct 10, 2025
Last update
Apr 22, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion